Tuesday, May 26, 2015

Acetazolamide for Idiopathic intracranial hypertension

Available product: 
Acetomid/Acetazolamide 250mg Tab (short acting)
Mechanism of Action
  • Carbonic anhydrase inhibitors are believed to reduce the rate of cerebrospinal fluid production. 

Indication
  • usual first line treatment for IIH (appears to be the most effective agent for lowering ICP)
  • Most patients experience adequate relief of symptoms (typically, headache)
  • However, evidence supporting its efficacy is mostly observational

Dosing
Adults
  • 500 mg twice per day and advance the dose as required and tolerated by the patient.
  • Although doses of up to 2 to 4 g per day can be administered, many patients develop dose limiting side effects at higher levels
  • sustained release formulation (Diamox sequels) may be better tolerated

Children
  • 25mg/kg per day with a maximum dose of 100 mg/kg or 2 g per day
  • 25-50mg/kg TDS-QID with Frusemide 0.25mg/kg QID (Frank Shann recommendation for TB Hydroencephalus)

Interaction
  • Although a sulfa allergy is reported to be a relative contraindication to acetazolamide use, there is little clinical or pharmacologic basis for this recommendatio
  • cross-reaction between sulfonamide antimicrobials and the sulfa moiety in acetazolamide and furosemide is unlikely
  • For patients who have had major adverse reactions (eg, Stevens-Johnson syndrome, anaphylaxis), we usually consider that the risk precludes the use of acetazolamide. Allergy consultation or other desensitization protocols may be considered in these patients.
  • However, if the previous sulfa-related reaction was minor, we usually proceed with acetazolamide treatment

Side Effects and Monitoring
  • usually dose-related.
  • Monitoring of electrolytes is suggested during acetazolamide treatment.
  • digital and oral paresthesias, anorexia, malaise, metallic taste, fatigue, nausea, vomiting, electrolyte changes, mild metabolic acidosis, and kidney stones


References:
  1. www.uptodate.com
  2. http://emedicine.medscape.com/article/1214410-treatment#aw2aab6b6b2
  3. Idiopathic Intracranial Hypertension. Neurol Clin. 2010 Aug; 28(3): 593–617.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.